Clinical Trial Update: Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma [Phase 1]

View source ↗

Summary

Phase 1 study of Galinpepimut-S in combination with nivolumab for pleural mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pleural Mesothelioma

Drugs mentioned

• Galinpepimut-S
• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Mesothelioma, Pleural Mesothelioma | Phase 1 | Status: COMPLETED